Literature DB >> 4115706

Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia.

B Bennett, O D Ratnoff, J Levin.   

Abstract

Antihemophilic globulin (AHF, factor VIII) levels were measured by a standard coagulation assay and by an immunological technique before and serially after infusion of fresh frozen plasma or cryoprecipitate into patients with von Willebrand's disease. Initial levels of AHF, measured both as procoagulant and as antigen, were low. Immediately after transfusions, the rise in levels of AHF-like antigen was compatible with the quantity of antigen present in the infused plasma or cryoprecipitate. Thereafter, levels of antigen declined rapidly and reached preinfusion values in approximately 24 hr. In contrast, procoagulant activity remained elevated, and sometimes continued to rise, for longer periods of time. One possible explanation of this finding is that the AHF molecule produced by patients with von Willebrand's disease, in response to transfusion of as yet unidentified factors, lacks the antigenic site associated with the normal AHF molecule or the inactive molecule produced by patients with hemophilia A.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4115706      PMCID: PMC332958          DOI: 10.1172/JCI107077

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  13 in total

1.  Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease.

Authors:  B N Bouma; Y Wiegerinck; J J Sixma; J A Van Mourik; I A Mochtar
Journal:  Nat New Biol       Date:  1972-03-29

2.  The immunological properties of factor VIII. II. The immunoelectrophoretic studies.

Authors:  L Uszyński
Journal:  Thromb Diath Haemorrh       Date:  1967-12-31

3.  Exercise, factor VIII and the spleen.

Authors:  C R Rizza; J Eipe
Journal:  Br J Haematol       Date:  1971-06       Impact factor: 6.998

4.  Two types of haemophilia (A+ and A-): a study of 48 cases.

Authors:  K W Denson; R Biggs; M E Haddon; R Borrett; K Cobb
Journal:  Br J Haematol       Date:  1969-08       Impact factor: 6.998

5.  Measurement of platelet adhesiveness: progress report.

Authors:  E W Salzman
Journal:  Thromb Diath Haemorrh Suppl       Date:  1967

6.  Immunological differentiation of three types of haemophilia and identification of some female carriers.

Authors:  E Bennett; E R Huehns
Journal:  Lancet       Date:  1970-11-07       Impact factor: 79.321

7.  Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease.

Authors:  D P Stites; E J Hershgold; J D Perlman; H H Fudenberg
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

8.  Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.

Authors:  B Bennett; O D Ratnoff
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

9.  Immunologic studies of antihemophilic factor (AHF, factor VIII). 3. Comparative binding properties of human and rabbit anti-AHF.

Authors:  L W Hoyer
Journal:  Blood       Date:  1972-04       Impact factor: 22.113

10.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

View more
  12 in total

1.  The effects of epinephrine infusion in patients with von Willebrand's disease.

Authors:  F R Rickles; L W Hoyer; M E Rick; D J Ahr
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

2.  Problems in the detection of carriers of haemophilia A.

Authors:  D Meyer; A Plas; J P Allain; G M Sitar; M J Larrieu
Journal:  J Clin Pathol       Date:  1975-09       Impact factor: 3.411

3.  Willebrand factor in von Willebrand's disease.

Authors:  F E Boulton; M J Lloyd
Journal:  Br Med J       Date:  1975-11-15

4.  Subunit structure of factor VIII antigen synthesized by cultured human endothelial cells.

Authors:  E A Jaffe; R L Nachman
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

5.  Factor VIII-related antigen in tissues detected by the indirect immunofluorescence technique.

Authors:  R Gruson; C R Rizza
Journal:  Blut       Date:  1974-10

6.  Macromolecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion.

Authors:  T R Griggs; J S Potter; S B McClanahan; W P Webster; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

7.  Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease.

Authors:  H R Gralnick; B S Coller; Y Sultan
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

8.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

9.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

10.  Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.

Authors:  B Bennett; O D Ratnoff
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.